ReviewBest practice & research. Clinical rheumatology2016
Cancer and autoimmunity: Harnessing longitudinal cohorts to probe the link.
Review in Best practice & research. Clinical rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 39 citations in OpenAlex.
- Intersection Between Systemic Autoimmune Diseases, Primary Immunodeficiency and Cancer: a Field in its Infancy.Journal of clinical immunology · 2026Review
- Head and neck cancer risk in patients with rheumatoid arthritis compared with matched controls: a nationwide cohort study.RMD open · 2026Article
- Sarcoma in patients with systemic lupus erythematosus. A systematic review.Reumatologia · 2026Review
- Leukemias in the Context of Rheumatoid Arthritis: Shared Pathways and Clinical Perspectives.Cureus · 2025Review
- Complete remission of unresectable advanced esophageal squamous cell carcinoma following nivolumab immunotherapy after chemoradiotherapy: a case report.International cancer conference journal · 2025Article
- Insights into autoimmunity and cancer.Nature immunology · 2025Article
- Article
- Immune-Mediated Inflammatory Diseases and Cancer - a dangerous liaison.Frontiers in immunology · 2024Review
- Malignancies in systemic rheumatic diseases: A mini review.Frontiers in immunology · 2023Review
- Diagnostic challenges of neurosarcoidosis in non-endemic areas.Frontiers in neurology · 2023Article
- Immunomodulatory effects of Blaps rynchopetera extract.Acta cirurgica brasileira · 2022Article
- Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications.Arthritis care & research · 2021Article
- Autoimmune Responses in Oncology: Causes and Significance.International journal of molecular sciences · 2021Review
- Cancer and Scleroderma.Rheumatic diseases clinics of North America · 2020Review
- The relationships between cancer and autoimmune rheumatic diseases.Best practice & research. Clinical rheumatology · 2020Review
- Risk of Cancers in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results from the Korea National Health Insurance Claims Database 2010-2018.Journal of clinical medicine · 2019Article
- Malignancy risk in Korean male patients with ankylosing spondylitis.Rheumatology international · 2019Article
- Dually Efficacious Medicine Against Fibrosis and Cancer.Medical sciences (Basel, Switzerland) · 2019Review
- PTEN Hamartoma Tumor Syndrome and Immune Dysregulation.Translational oncology · 2019Review
- Effects of Transitioning to Medicare Part D on Access to Drugs for Medical Conditions among Dual Enrollees with Cancer.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
In many autoimmune rheumatic diseases, there is an increased risk of cancer compared to the general population. While reasons for this increased risk have not been elucidated, it has been hypothesized that the link between cancer and autoimmunity may be bidirectional. For instance, chronic inflammation and damage from the rheumatic disease or its therapies may trigger malignant transformation; conversely, antitumor immune responses targeting cancers may become cross-reactive resulting in autoimmunity. In rare rheumatic diseases, longitudinal observational studies can play a critical role in studying these complex relationships, thereby enabling investigators to quantify the extent of cancer risk, identify unique clinical phenotypes associated with cancer, investigate the biological link between these conditions, and define optimal strategies for screening and treatment of the underlying cancer. In this review, we discuss recent data on cancer in the rheumatic diseases and suggest a research agenda to address several gaps in our current knowledge base.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.